

**From:** [Lisa Renda](#)  
**To:** [Antonio Gudino-Vargas](#)  
**Cc:** [Pharmacy Services](#)  
**Subject:** Lilly Medical Information\_Established Drug Class\_Migraine  
**Date:** Thursday, November 18, 2021 9:39:06 AM  
**Attachments:** [image001.jpg](#)  
[Emgality Medical Value Summary 11.18.21.pdf](#)

---

Hi Antonio,

In preparation for the December 9, 2020 Sliver State Scripts Board meeting, I have attached the updated medical value summary for Emgality (galcanczemb-gnlm) as requested on the Nevada Department of Health and Human Services, Division of Health care Financing and Policy Provider Portal. Please let me know if there are any questions or need for additional information.

This information is intended only as a scientific exchange in response to your request and is not intended for product promotion. This information may contain substantive discussion of developmental compound(s) not approved for marketing in the United States and/or products approved for marketing in the United States but for uses, dosages, formulations and/or populations different than those discussed in these materials. If the information you have requested contains a substantive discussion of a currently marketed product(s), a link to the U.S. Prescribing Information for that product(s) is included in this message. You should consult this prescribing information for the product's approved uses and important safety information, including boxed warnings, regarding the product's use.

To review prescribing information please visit: <http://pi.lilly.com/us/emgality-uspi.pdf>

If an article is provided, this literature is protected by U.S. and international copyright laws. No additional reproduction or distribution is authorized. Complete credit should be given to the original source. If an article from the *New England Journal of Medicine* is included, this literature is copyrighted by the Massachusetts Medical Society. All rights reserved. It is provided for your personal informational use only.

If you are a covered recipient under the Physician Payment Sunshine Act (effective August 1, 2013) and you request Lilly to make a copyright payment for any of the above materials, then the fair market value of those materials including any incurred shipping costs will be reported to the Centers for Medicare and Medicaid Services (CMS) and disclosed on a public website as a transfer of value provided to you.

We hope this information is responsive to your request. If you have any questions, please contact me at [lrenda@lilly.com](mailto:lrenda@lilly.com). In addition, you may contact The Lilly Answers Center at 1-800-LILLYRX (1-800-545-5979) or visit [www.lilly.com](http://www.lilly.com).

Regards,  
Lisa

**Lisa Renda, RN, MSN**  
Consultant-Evidence & Outcomes Liaison  
Global Patient Outcomes & Real World Evidence  
**Eli Lilly and Company**  
480.276.0074 (mobile)

[lrenda@lilly.com](mailto:lrenda@lilly.com) | [www.lilly.com](http://www.lilly.com)



CONFIDENTIALITY NOTICE: This email message (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. For more information about Lilly's privacy practice, please view our [Privacy Statement](#).